Elicera Therapeutics AB (publ)
STO: ELIC.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jamal El-Mosleh
- Employees
- 2
- Headquarters
- Gothenburg, Sweden
- IPO year
- 2021
- Market cap
- SEK 157.7M
- Website
- https://www.elicera.com
Loading ELIC…
Loading profile data…Frequently asked questions about ELIC
What does Elicera Therapeutics AB (publ) (ELIC.ST) do?
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell...
Where does ELIC.ST trade?
Elicera Therapeutics AB (publ) (ELIC.ST) trades on the Stockholm Stock Exchange.
What sector is ELIC.ST in?
Elicera Therapeutics AB (publ) (ELIC.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Elicera Therapeutics AB (publ)?
Jamal El-Mosleh is the chief executive officer of Elicera Therapeutics AB (publ) (ELIC.ST).
Where is Elicera Therapeutics AB (publ) headquartered?
Elicera Therapeutics AB (publ) is headquartered in Sweden.
Does ELIC.ST pay a dividend?
Elicera Therapeutics AB (publ) (ELIC.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ELIC.ST go public?
Elicera Therapeutics AB (publ) (ELIC.ST) completed its initial public offering in 2021.